Clinical Trials Logo

Clinical Trial Summary

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as the Churg-Strauss syndrome, is a systemic necrotizing vasculitis that affects small and medium sized blood vessels. NUCALA® (mepolizumab 300 milligrams [mg], subcutaneous administration) was approved in Japan in 2018 for the treatment of EGPA in adult participants. This is a single-arm, multi-center, prospective, non-interventional study that aims to assess long-term (2 to 4 years) real-world safety and effectiveness of NUCALA. Approximately 120 participants who completed the NUCALA Post Marketing Surveillance (PMS) study (National Clinical Trial [NCT]03557060) will be enrolled in the study. NUCALA is a registered trademark of GlaxoSmithKline (GSK) group of companies.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04551989
Study type Observational
Source GlaxoSmithKline
Status Active, not recruiting
Start date December 11, 2020
Completion date April 3, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01729624 - PRO Development for ANCA Associated Vasculitis N/A
Completed NCT02190916 - Vasculitis Illness Perception (VIP) Study N/A
Recruiting NCT02967068 - VCRC Tissue Repository
Completed NCT02190942 - VCRC Patient Contact Registry Patient-Reported Data Validation Study
Completed NCT00307593 - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides N/A
Completed NCT02190929 - Educational Needs of Patients With Systemic Vasculitis N/A
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Active, not recruiting NCT03557060 - NUCALA® Special Drug Use Investigation (EGPA, Long-term)
Terminated NCT00424749 - Rituxan in Churg Strauss Syndrome With Renal Involvement Phase 2
Completed NCT00307671 - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Phase 4
Active, not recruiting NCT00399399 - CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Phase 4
Completed NCT02020889 - A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Phase 3
Completed NCT02176070 - Reproductive Health in Men and Women With Vasculitis N/A
Completed NCT00266565 - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Phase 1/Phase 2
Recruiting NCT06046222 - Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Phase 2
Recruiting NCT04316494 - Hydroxychloroquine in ANCA Vasculitis Evaluation Phase 4
Recruiting NCT04671446 - Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Completed NCT03036670 - Eosinophilic Granulomatosis With Polyangiitis Cohort
Terminated NCT02728271 - Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome Early Phase 1
Recruiting NCT00315380 - Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis